Glaxosmithkline Pharmaceuticals trades higher on reporting many fold jump in Q4 consolidated net profit
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Glaxosmithkline Pharmaceuticals is currently trading at Rs. 1518.75, up by 4.65 points or 0.31% from its previous closing of Rs. 1514.10 on the BSE.
The scrip opened at Rs. 1542.00 and has touched a high and low of Rs. 1560.00 and Rs. 1509.85 respectively. So far 5245 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1917.00 on 13-Dec-2021 and a 52 week low of Rs. 1433.05 on 12-May-2022.
Last one week high and low of the scrip stood at Rs. 1560.00 and Rs. 1433.05 respectively. The current market cap of the company is Rs. 25728.54 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 12.91% and 12.09% respectively.
Glaxosmithkline Pharmaceuticals has reported many fold jump in its net profit at Rs 1217.84 crore for fourth quarter and year ended March 31, 2022 as compared to Rs 12.75 crore for the same quarter in the previous year. Total income of the company increased by 5.64% at Rs 810.86 crore for Q4FY22 as compared Rs 767.56 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported many fold jump in its net profit at Rs 1219.05 crore for fourth quarter and year ended March 31, 2022 as compared to Rs 14.33 crore for the same quarter in the previous year. Total income of the company increased by 7.02% at Rs 828.39 crore for Q4FY22 as compared Rs 774.03 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported above 4-fold jump in its net profit at Rs 1690.53 crore as compared to Rs 357.57 crore for the previous year. Total income of the company increased by 8.68% at Rs 3293.73 crore for year under review as compared to Rs 3030.66 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported above 4-fold jump at Rs 1694.72 crore as compared to Rs 358.15 crore for the previous year. Total income of the company increased by 10.46% at Rs 3353.81 crore for year under review as compared to Rs 3036.18 crore for year ended March 31, 2021.
